Johnson & Johnson (JNJ)
Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson tops Q1 expectations, lifts 2025 sales outlook
Johnson & Johnson (NYSE:JNJ) reported its first quarter earnings, with both revenue and profit beating Wall Street expectations driven by strong sales in its oncology portfolio, especially the multiple myeloma drug Darzalex. Revenue was up 2.4% year-over-year at $21.89 billion, ahead of estimates of $21.56 billion.
Johnson & Johnson raised its sales outlook, even with tariff costs included
Johnson & Johnson beat Wall Street's expectations for first-quarter profit and revenue on Tuesday, as strong growth in the U.S. offset weakness internationally.
Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook
Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.
J&J Increases Outlook After Beating 1Q Expectations
Johnson & Johnson now expects sales of up to $91.8 billion in 2025, compared with a prior view of up to $90 billion.
Johnson & Johnson: Fairly Valued, But Recession-Resilient
Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate growth in sales and earnings, with notable performance in the oncology and cardiovascular segments. Analysts expect low-to-mid single-digit growth for Johnson & Johnson, with a focus on operational efficiency and share buybacks to boost the bottom line.
Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Pharma tariffs unlikely to hit earnings before 2026, analysts say
Potential tariffs on pharmaceuticals under the Trump administration would take more time to have an impact on the sector than investors may realize, analysts at Bank of America believe. US president Donald Trump said on Tuesday that the country would soon be announcing a “major tariff” on pharmaceuticals with the aim of onshoring drug manufacturing.
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Both JNJ & PFE expect their sales and profits to improve in 2025.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Shares of Johnson & Johnson JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.
S&P 500 Gains and Losses Today: Johnson & Johnson Drops as Judge Rejects Liability Settlement
Major U.S. equities indexes finished the first trading day of the second quarter mixed.
